| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/22/1999 | WO1998052548A3 Use of 1-ar(alk)yl-imidazolin-2-one for treating anxiety and stress conditions |
| 04/22/1999 | WO1998050383A8 5-phenyl-1,3,4-oxadiazol-2(3h)-one derivatives and their use as 5-ht4 ligands |
| 04/22/1999 | WO1998044021A9 Biodegradable terephthalate polyester-poly(phosphate) polymers, compositions, articles, and methods for making and using the same |
| 04/22/1999 | WO1998043618A9 Use of cytoskeletal inhibitors for the prevention of restenosis |
| 04/22/1999 | WO1998036779A3 System for the in vivo delivery and expression of heterologous genes in the bone marrow |
| 04/22/1999 | WO1998030203A3 Transdermal therapeutic system |
| 04/22/1999 | WO1998021221A3 1-thiogalactose derivatives |
| 04/22/1999 | DE19847781A1 Pharmaceutical preparations containing PETN or metabolite useful in treatment of cardiac, circulatory, and cerebrovascular disorders |
| 04/22/1999 | DE19745583A1 New actagardine derivatives with extra N-terminal amino acid |
| 04/22/1999 | DE19745485A1 Reducing neurological damage in Gram positive bacterial meningitis using a protein kinase inhibitor |
| 04/22/1999 | CA2792406A1 Methods for encapsulating nucleic acids in lipid bilayers |
| 04/22/1999 | CA2696653A1 Mammalian genes involved in viral infection and tumor suppression |
| 04/22/1999 | CA2316296A1 Use of csaidtm compounds for the management of uterine contractions |
| 04/22/1999 | CA2315244A1 Transgenic animal models for cardiac hypertrophy and uses thereof |
| 04/22/1999 | CA2308143A1 Pharmaceutical formulation comprising glycine as a stabilizer |
| 04/22/1999 | CA2307929A1 Upregulation of type iii endothelial cell nitric oxide synthase by hmg-coa reductase inhibitors |
| 04/22/1999 | CA2307208A1 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| 04/22/1999 | CA2306851A1 Synthetic methods for polyphenols |
| 04/22/1999 | CA2306811A1 Piperazine compounds and medicinal use thereof |
| 04/22/1999 | CA2306789A1 Pyridyl compounds and pharmaceutical compositions containing them |
| 04/22/1999 | CA2306766A1 Use of sulfated oligosaccharides in lowering blood triglyceride levels |
| 04/22/1999 | CA2306479A1 Percutaneously absorbable preparation |
| 04/22/1999 | CA2306448A1 Models and treatments for cardiac hypertrophy in relation with nf-at3 function |
| 04/22/1999 | CA2306444A1 Inhibition of human immunodeficiency virus (hiv-1) replication |
| 04/22/1999 | CA2306443A1 Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities |
| 04/22/1999 | CA2306423A1 Methods for increasing schwann cell survival |
| 04/22/1999 | CA2306420A1 Iso-cbi and iso-ci analogs of cc-1065 and the duocarmycins |
| 04/22/1999 | CA2306399A1 Antibacterial carbapenems, compositions and methods of treatment |
| 04/22/1999 | CA2306344A1 Method of building and maintaining bone |
| 04/22/1999 | CA2306276A1 Pharmaceutically active compound and methods of use |
| 04/22/1999 | CA2306096A1 Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal |
| 04/22/1999 | CA2306086A1 Use of thiazolidinediones for the treatment of hyperglycaemia |
| 04/22/1999 | CA2306076A1 Combinatorial preparation of phosphinic acid derivatives |
| 04/22/1999 | CA2305801A1 Ethyl 4-(8-chloro-5, 6-dihydro-11h- benzo[5,6]cyclohepta [1,2-b]pyridin -11-ylidene)-1- piperidene carboxylate polymorph |
| 04/22/1999 | CA2305703A1 Compositions and methods for inhibiting arginase activity |
| 04/22/1999 | CA2305614A1 Method for preparing substituted 4-phenyl-4-cyanocyclohexanoic acids |
| 04/22/1999 | CA2305499A1 Novel pharmaceutically active compounds, their preparation and use as ece-inhibitors |
| 04/22/1999 | CA2305353A1 Heterocycles useful in the treatment of benign prostatic hyperplasia and intermediates thereof |
| 04/22/1999 | CA2305289A1 Use of thiazolidinediones for the treatment of hyperglycaemia |
| 04/22/1999 | CA2305277A1 Antipsychotic substituted piperidine derivatives |
| 04/22/1999 | CA2305262A1 Method for treating alzheimer's disease |
| 04/22/1999 | CA2305255A1 Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
| 04/22/1999 | CA2305180A1 Ih-modulators |
| 04/22/1999 | CA2305141A1 Novel combination |
| 04/22/1999 | CA2304979A1 Pyrazole derivatives having a calcium release-activated calcium channel inhibitory effect |
| 04/22/1999 | CA2304493A1 Flavonolignan preparations, especially silymarin preparations |
| 04/22/1999 | CA2304473A1 Inhibitors of farnesyl protein transferase |
| 04/22/1999 | CA2304457A1 Mixed cyanoacrylate ester compositions |
| 04/22/1999 | CA2304379A1 Benzimidazole compounds, pharmaceutical compositions containing the compounds and their use |
| 04/22/1999 | CA2304374A1 Method of preventing nephrotoxicity caused by cyclosporins and tacrolimus |
| 04/22/1999 | CA2303935A1 12(s)-hete receptor blockers |
| 04/22/1999 | CA2301800A1 Thioalkyl alpha substituted pyrimidine compounds |
| 04/22/1999 | CA2274708A1 Remedial composition for intraocular hypertension or glaucoma |
| 04/22/1999 | CA2248762A1 Antisense oligodeoxynucleotides regulating expression of tnf-.alpha. |
| 04/21/1999 | EP0909820A2 Histidine kinase from Staphylococcus pneumoniae |
| 04/21/1999 | EP0909768A2 Process for removing bile salts from a patient and alkylated compositions therefor |
| 04/21/1999 | EP0909763A2 Colchicine derivatives and the therapeutical use thereof |
| 04/21/1999 | EP0909759A2 Individual stereoisomers of 7-(3-aminoalkyl)-1-pyrrolidinyl)-quinolones as antibacterial agents |
| 04/21/1999 | EP0909758A1 Dithiolylidene acetamide derivatives |
| 04/21/1999 | EP0909562A1 Injections containing lipid a analogues and process for the preparation thereof |
| 04/21/1999 | EP0909561A2 Use of reboxetine for the treatment of attention-deficit/hyperactivity disorder |
| 04/21/1999 | EP0909560A2 Treatment o tumors with compounds having RXR retinoid receptor agoinst activity |
| 04/21/1999 | EP0909559A2 Use of inhibitors of the sodium hydrogen exchange in the manufacture of a medicament for treatment or prophylaxis of diseases of the central nervous system |
| 04/21/1999 | EP0909558A2 Chroman derivative containing ophthalmic solution |
| 04/21/1999 | EP0909557A1 Use of honey as an agent for decreasing micro-organisms adhesion |
| 04/21/1999 | EP0909556A1 Rosaceae extract as bradykinin antagonist |
| 04/21/1999 | EP0909330A1 Diagnostic method and apparatus |
| 04/21/1999 | EP0909327A2 Erythromycins and process for their preparation |
| 04/21/1999 | EP0909316A1 Glial cell line-derived neurotrophic factor receptor |
| 04/21/1999 | EP0909271A1 Indolyl-pyrrolydenemethylpyrrole derivatives and process for their preparation |
| 04/21/1999 | EP0909268A1 Method for preparing substituted anthraquinone and application to the preparation of rheins |
| 04/21/1999 | EP0909184A2 Targeted drug delivery using sulfonamide derivatives |
| 04/21/1999 | EP0909183A2 Dha-pharmaceutical agent conjugates |
| 04/21/1999 | EP0909182A2 Method for producing chlorins and bacteriochlorins containing polyether |
| 04/21/1999 | EP0909181A1 Novel compounds |
| 04/21/1999 | EP0909174A1 TREATMENT OF CYSTIC DISEASE WITH TNF-$g(a) |
| 04/21/1999 | EP0909173A1 Topical administration of certain azaspiranes to prevent or treat skin conditions associated with hyperproliferation of skin cells and/or immunologically mediated disorders |
| 04/21/1999 | EP0909171A1 Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1 |
| 04/21/1999 | EP0909170A1 Methods and compositions for treating urinary incontinence using enantiomerically enriched (s)-tridihexethyl |
| 04/21/1999 | EP0909169A1 Medical use |
| 04/21/1999 | EP0909168A2 Propellant mixtures and aerosols for micronising medicaments with compressed gas |
| 04/21/1999 | EP0909163A1 Methods and compositions for treating urinary incontinence using enantiomerically enriched (s,r)-glycopyrrolate |
| 04/21/1999 | EP0909132A1 Dietetic foods containing conjugated linoleic acids |
| 04/21/1999 | EP0885217A4 Endothelin receptor antagonists |
| 04/21/1999 | EP0882039A4 Endothelin receptor antagonists |
| 04/21/1999 | EP0859635B1 Stabilised pharmaceutical compositions containing dobutamine |
| 04/21/1999 | EP0793641B1 Metalloproteinase inhibitors |
| 04/21/1999 | EP0743938B1 Substituted spiro compounds for the treatment of inflammation |
| 04/21/1999 | EP0717731B1 Difluoro statone antiviral analogs |
| 04/21/1999 | EP0712397B1 Amide derivatives as 5ht1d receptor antagonists |
| 04/21/1999 | EP0690671A4 Method and apparatus for encapsulation of biologically-active substances in cells |
| 04/21/1999 | EP0644947B1 Anti-idiotypic monoclonal antibodies against the lewis y-specific monoclonal antibody br55-2 and their uses |
| 04/21/1999 | EP0633261B1 Quinoline-3-acetic acid derivative, process for producing the same, and use thereof |
| 04/21/1999 | EP0369000B1 Macrocyclic complexes of yttrium, the lanthanides and the actinides having peripheral coupling functionalities |
| 04/21/1999 | CN1214734A SCF analog compositions and method |
| 04/21/1999 | CN1214695A ErdB3 antibodies |
| 04/21/1999 | CN1214690A Specific immunophilin ligands as antiasthmatics and immunosuppressants |
| 04/21/1999 | CN1214686A Derivatives of camptothecin for use in treating cancer |
| 04/21/1999 | CN1214685A Inhibitors of farnesyl protein transferase |
| 04/21/1999 | CN1214682A Eprosartan dihydrate and process for its production and formulation |